Gabriel C. De Santana - Publications

From clinical to immunologic remission in lupus nephritis: Toward MRD-grade B-cell depletion.

Journal: Lupus

Published: June 03, 2026

Renal toxicity during VEGF-pathway inhibition in cancer: a practical review of proteinuria, hypertension, and kidney-limited thrombotic microangiopathy.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 16, 2026

Zilebesiran in Hypertension: Reversibility, Acute Illness, and Therapeutic Flexibility.

Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions

Published: March 31, 2026

Peri-Transplant APOL1 Pore Inhibition in High-Risk Donor Kidneys: A Testable Hypothesis.

Journal: Nephron

Published: March 11, 2026

Aprocitentan in resistant hypertension with chronic kidney disease: balancing albuminuria reduction against early volume risk.

Journal: Journal of human hypertension

Published: March 10, 2026

From daily burden to scheduled protection: the "vaccine-like" shift in hypertension.

Journal: Journal of human hypertension

Published: February 23, 2026

Tenapanor Beyond Phosphate: Gut Sodium Transport, Stool Transit, and Volume Balance in Dialysis.

Journal: Hemodialysis international. International Symposium on Home Hemodialysis

Published: February 23, 2026

The neuroimmune architecture of uremic pruritus: mechanisms and therapeutic targeting.

Journal: Journal of nephrology

Published: February 05, 2026